Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer

被引:20
|
作者
Sasaki, M
Sugio, K
Kuwabara, Y
Koga, H
Nakagawa, M
Chen, T
Kaneko, K
Hayashi, K
Shio-Yama, Y
Sakai, S
Honda, H
机构
[1] Kyushu Univ, Dept Clin Radiol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan
关键词
lung cancer; FDG; PET; tumor suppressor gene;
D O I
10.1007/BF02990021
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: The FDG uptake in lung cancer is considered to reflect the degree of malignancy, while alterations of some tumor suppressor genes are considered to be related to the malignant biological behavior of tumors. The aim of this study is to examine the relationship between FDG-PET and alterations in the tumor suppression genes of lung cancer. Methods: We examined 28 patients with primary lung cancer who underwent FDG-PET before surgery consisting of 17 patients with adenocarcinoma, 10 with squamous cell carcinoma and I with large cell carcinoma. The FDG-PET findings were evaluated based on the standardized uptake value (SUV). Alterations in the tumor suppressor genes, Rb, p16, p27 and p53, were evaluated immunohistochemically. Results: The FDG uptake in lung cancer with alteration in each tumor suppressor gene tended to be higher than in those genes without alterations, although the differences were not significant. In 15 tumors with alterations in either tumor suppressor genes, the FDG uptake was 6.83 +/- 3.21. On the other hand, the mean FDG uptake was 1.95 in 2 tumors without alterations in any genes. The difference in the FDG uptake between the 2 groups was statistically significant (p < 0.001). Conclusions: In conclusion, the presence of abnormalities in the tumor suppressor genes, which results in an accelerated cell proliferation, is thus considered to increase the FDG uptake in lung cancer.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 50 条
  • [31] Expression of p27 and p16 and their clinical significance in gastric cancer
    S. Kumari
    P. Kumar
    M. Kumar
    S. Singh
    G. Narayan
    Clinical and Translational Oncology, 2021, 23 : 856 - 865
  • [32] Therapeutic approaches based on the reintroduction of tumour suppressor genes p16 and p53 in human pancreatic cancer.
    Calbó, J
    Cascalló, M
    Roig, JM
    Mazo, A
    CLINICAL CANCER RESEARCH, 2000, 6 : 4568S - 4568S
  • [33] Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer
    Abat, Deniz
    Demirhan, Osman
    Inandiklioglu, Nihal
    Tunc, Erdal
    Erdogan, Seyda
    Tastemir, Deniz
    Uslu, Inayet Nur
    Tansug, Zuhtu
    ONCOLOGY LETTERS, 2014, 8 (01) : 25 - 32
  • [34] Alterations in the p16INK4a and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts
    Jane R Noble
    Ze-Huai Zhong
    Axel A Neumann
    John R Melki
    Susan J Clark
    Roger R Reddel
    Oncogene, 2004, 23 : 3116 - 3121
  • [35] Alterations in the p16INK4a and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts
    Noble, JR
    Zhong, ZH
    Neumann, AA
    Melki, JR
    Clark, SJ
    Reddel, RR
    ONCOGENE, 2004, 23 (17) : 3116 - 3121
  • [36] p27: tumor suppressor and oncogene ...?
    Uta Kossatz
    Nisar P Malek
    Cell Research, 2007, 17 : 832 - 833
  • [37] P27: tumor suppressor and oncogene ...?
    Kossatz, Uta
    Malek, Nisar P.
    CELL RESEARCH, 2007, 17 (10) : 832 - 833
  • [38] P27: tumor suppressor and oncogene?
    Besson, Arnaud
    M S-MEDECINE SCIENCES, 2007, 23 (12): : 1089 - 1091
  • [39] Genetic alterations of p16(INK4a) and p53 genes in sporadic dysplastic nevus
    Lee, JY
    Dong, SM
    Shin, MS
    Kim, SY
    Lee, SH
    Kang, SJ
    Lee, JD
    Kim, CS
    Kim, SH
    Yoo, NJ
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 237 (03) : 667 - 672
  • [40] Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas
    Tsuzuki, T
    Tsunoda, S
    Sakaki, T
    Konishi, N
    Hiasa, Y
    Nakamura, M
    CANCER, 1996, 78 (02) : 287 - 293